BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces positive survival data in its phase II clinical trial with doxorubicin Transdrug® in patients with advanced hepatocellular carcinoma (primary liver cancer).
(read here…)

People who looked at this item also looked at…

• Cyrium Technologies Introduces QDEC Product Line: High Efficiency Concentrator Photovoltaic (CPV) Solar Cells (Business Wire via Yahoo! Finance)
• ‘Smart’ nanocapsule delivery system created for use in protein therapy (Science Daily)
• Doxorubicin Transdrug®: Significant increased survival rate in patients with advanced hepatocellular carcinoma treated … (Business Wire via Yahoo! Finance)
• Bayer’s NEXAVAR approved in over 70 countries for the treatment of liver cancer (News-Medical-Net)

Related items

• Doxorubicin Transdrug(R): Significant Increased Survival Rate In Patients With Advanced Hepatocellular Carcinoma … (Medical News Today)
• Doxorubicin Transdrug®: Significant increased survival rate in patients with advanced hepatocellular carcinoma treated … (Business Wire via Yahoo! Finance)
• Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting
• Going For Gold With A Novel Interventional Radiology Treatment For Pancreatic Cancer (Medical News Today)
• Going For Gold With Novel Interventional Radiology Treatment For Pancreatic Cancer (redOrbit)

Tags: aids patients, BioAlliance, bioalliance pharma, cancer, company, hepatocellular carcinoma, liver cancer, nano, nanotech, nanotechnology, Pharma, primary liver cancer, survival data, Technology, treatment

This entry was posted on December 9, 2009 at 10:56 am and is filed under Technology.